Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · see citing works

International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126 · see citing works

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · see citing works

A role for glucagon-like peptide-1 in the central regulation of feeding

Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · see citing works

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · see citing works

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · see citing works

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · see citing works

Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus

Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · see citing works

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · see citing works

The incretin concept today

Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · see citing works

The gut and energy balance: visceral allies in the obesity wars

Badman, M. K., & Flier, J. S. (2005) · Science · doi:10.1126/science.1109951 · Cited by 532 · see citing works

International Union of Pharmacology. XXXV. The Glucagon Receptor Family

Mayo, K. E., Miller, L. J., BATAILLE, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 507 · see citing works

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

Nauck, M. A., Bartels, E., Ørskov, C., Ebert, R., & Creutzfeldt, W. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.4.8473405 · Cited by 505 · see citing works

Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis

Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 484 · see citing works

Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice

Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · see citing works

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440 · see citing works

Entero-Insular Axis

Unger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · see citing works

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · see citing works

Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors

Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309 · see citing works

Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis

Drucker, D. J. (2003) · Endocrinology · doi:10.1210/en.2003-1147 · Cited by 274 · see citing works

GIF biology and fat metabolism

Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266 · see citing works

Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors

Preitner, F., Ibberson, M. R., Franklin, I., Binnert, C., Pende, M., Gjinovci, A., Hansotia, T., Drucker, D. J., Wollheim, C. B., Burcelin, R., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20518 · Cited by 254 · see citing works

Gastric Inhibitory Polypeptide as an Endogenous Factor Promoting New Bone Formation after Food Ingestion

Tsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., et al. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0187 · Cited by 198 · see citing works

GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice

Hansotia, T., & Drucker, D. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.019 · Cited by 182 · see citing works

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.

Pederson, R. A., Satkunarajah, M., McIntosh, C. H. S., Scrocchi, L. A., Flamez, D., Schuit, F. C., Drucker, D. J., & Wheeler, M. B. (1998) · Diabetes · doi:10.2337/diabetes.47.7.1046 · Cited by 167 · see citing works

Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM

Dupre, J., Behme, M. T., HRAMIAK, I. M., McFarlane, P. A., Williamson, M. P., Zabel, P. L., & McDonald, T. J. (1995) · Diabetes · doi:10.2337/diab.44.6.626 · Cited by 152 · see citing works

β-Adrenergic Receptors and Regulation of Energy Expenditure: A Family Affair

Robidoux, J., Martin, T. L., & Collins, S. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121659 · Cited by 130 · see citing works

Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis

Pamir, N., Lynn, F. C., Buchan, A. M. J., Ehses, J., Hinke, S. A., Pospisilik, J. A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C. H. S., et al. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00270.2002 · Cited by 126 · see citing works

Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.

Scrocchi, L. A., Marshall, B. A., Cook, S., Brubaker, P. L., & Drucker, D. J. (1998) · Diabetes · doi:10.2337/diabetes.47.4.632 · Cited by 114 · see citing works

Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice

Scrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95 · see citing works

Glucagon-Like Peptide-1, But Not Glucose-Dependent Insulinotropic Peptide, Regulates Fasting Glycemia and Nonenteral Glucose Clearance in Mice

Baggio, L. L., Kieffer, T. J., & Drucker, D. J. (2000) · Endocrinology · doi:10.1210/endo.141.10.7720 · Cited by 79 · see citing works

Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene.

Flamez, D., Breusegem, A. V., Scrocchi, L. A., Quartier, E., PIPELEERS, D. G., Drucker, D. J., & Schuit, F. C. (1998) · Diabetes · doi:10.2337/diabetes.47.4.646 · Cited by 71 · see citing works

Characterization of GIP(1–30) and GIP(1–42) as stimulators of proinsulin gene transcription

Fehmann, H. C., & Göke, B. (1995) · Peptides · doi:10.1016/0196-9781(95)00090-7 · Cited by 50 · see citing works

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · see citing works

TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis

Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885 · see citing works

Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease

Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529 · see citing works

Pharmacology, physiology, and mechanisms of incretin hormone action.

Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · see citing works

Animal models of obesity and diabetes mellitus

Kleinert, M., Clemmensen, C., Hofmann, S. M., Moore, M. C., Renner, S., Woods, S. C., Huypens, P., Beckers, J., de Angelis, M. H., Schürmann, A., et al. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.161 · Cited by 853 · see citing works

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · see citing works

Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway

Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · see citing works

Cardiovascular Biology of the Incretin System

Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 527 · see citing works

GLP-1 physiology informs the pharmacotherapy of obesity

Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510 · see citing works

Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease

Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498 · see citing works

Impact of postprandial glycaemia on health and prevention of disease

Blaak, E. E., Antoine, J. M., Benton, D., Björck, I., Bozzetto, L., Brouns, F. J. P. H., Diamant, M., Dye, L., Hulshof, T. G., Holst, J. J., et al. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01011.x · Cited by 487 · see citing works

Pharmacotherapy of obesity: an update on the available medications and drugs under investigation

Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462 · see citing works

From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior

Williams, K. W., & Elmquist, J. K. (2012) · Nature Neuroscience · doi:10.1038/nn.3217 · Cited by 421 · see citing works

Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

Turcot, V., Lu, Y., Highland, H. M., Schurmann, C., Justice, A. E., Fine, R. S., Bradfield, J. P., Esko, T., Giri, A., Graff, M., et al. (2017) · Nature Genetics · doi:10.1038/s41588-017-0011-x · Cited by 410 · see citing works

Cardiovascular Actions of Incretin-Based Therapies

Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake

Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324 · see citing works

Adipokines and the Peripheral and Neural Control of Energy Balance

Ahima, R. S., & Lazar, M. A. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0529 · Cited by 314 · see citing works

Vertical Sleeve Gastrectomy Is Effective in Two Genetic Mouse Models of Glucagon-Like Peptide 1 Receptor Deficiency

Wilson, H., Chambers, A. P., Ryan, K. K., Li, B., Sandoval, D. A., Stoffers, D. A., Drucker, D. J., Pérez–Tilve, D., & Seeley, R. J. (2013) · Diabetes · doi:10.2337/db12-1498 · Cited by 286 · see citing works

GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R

Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282 · see citing works

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2009) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 276 · see citing works

Gastrojejunal Stoma Diameter Predicts Weight Regain After Roux-en-Y Gastric Bypass

Dayyeh, B. K. A., Lautz, D. B., & Thompson, C. C. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.11.004 · Cited by 267 · see citing works

Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1

Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244 · see citing works

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

McClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2007 · Cited by 237 · see citing works

FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice

Rached, M.-T., Kode, A., Silva, B. C. C., Jung, D. Y., Gray, S., Ong, H., Paik, J.-H., DePinho, R. A., Kim, J. K., Karsenty, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39901 · Cited by 228 · see citing works

GLP-1 and energy balance: an integrated model of short-term and long-term control

Barrera, J. G., Sandoval, D. A., D'Alessio, D. A., & Seeley, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.77 · Cited by 220 · see citing works

GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose

Iwasaki, Y., Sendo, M., Dezaki, K., Hira, T., Sato, T., Nakata, M., Goswami, C., Aoki, R., Arai, T., Kumari, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02488-y · Cited by 200 · see citing works

GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis

Kim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M., & McIntosh, C. H. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040156 · Cited by 182 · see citing works

Reappraisal of GIP Pharmacology for Metabolic Diseases

Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180 · see citing works

Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat Diet

Althage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., & Wice, B. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710466200 · Cited by 180 · see citing works

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM

Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174 · see citing works

Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice

Lamont, B. J., Li, Y., Kwan, E. P., Brown, T. J., Gaisano, H. Y., & Drucker, D. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42497 · Cited by 171 · see citing works

Exogenous Glucose–Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes

Chia, C. W., Carlson, O. D., Kim, W., Shin, Y., Charles, C. P., Kim, H. S., Melvin, D. L., & Egan, J. M. (2009) · Diabetes · doi:10.2337/db08-0958 · Cited by 174 · see citing works

Chapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)

McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 172 · see citing works

Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High-Fat Diet Conditions

Nasteska, D., Harada, N., Suzuki, K., Yamane, S., Hamasaki, A., Joo, E., Iwasaki, K., Shibue, K., Harada, T., & Inagaki, N. (2014) · Diabetes · doi:10.2337/db13-1563 · Cited by 171 · see citing works

Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice

Flock, G. B., Baggio, L. L., Longuet, C., & Drucker, D. J. (2007) · Diabetes · doi:10.2337/db07-0697 · Cited by 164 · see citing works

Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice

Koehler, J. A., Baggio, L. L., Lamont, B. J., Ali, S., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db09-0626 · Cited by 160 · see citing works

Minireview: Meeting the Demand for Insulin: Molecular Mechanisms of Adaptive Postnatal ß-Cell Mass Expansion

Sachdeva, M. M., & Stoffers, D. A. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0400 · Cited by 155 · see citing works

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153 · see citing works

Potential therapeutic interventions for chronic kidney disease‐associated sarcopenia via indoxyl sulfate‐induced mitochondrial dysfunction

Enoki, Y., Watanabe, H., Arake, R., Fujimura, R., Ishiodori, K., Imafuku, T., Nishida, K., Sugimoto, R., Nagao, S., Miyamura, S., et al. (2017) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12202 · Cited by 155 · see citing works

Hyperphagia and Increased Fat Accumulation in Two Models of Chronic CNS Glucagon-Like Peptide-1 Loss of Function

Barrera, J. G., Jones, K. R., Herman, J. P., D’Alessio, D. A., Woods, S. C., & Seeley, R. J. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2212-10.2011 · Cited by 154 · see citing works

GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications

Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149 · see citing works

Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling

Challa, T. D., Beaton, N., Arnold, M., Rudofsky, G., Langhans, W., & Wolfrum, C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.310342 · Cited by 149 · see citing works

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection

Ussher, J. R., Baggio, L. L., Campbell, J. E., Mulvihill, E. E., Kim, M., Kabir, M. G., Cao, X., Baranek, B. M., Stoffers, D. A., Seeley, R. J., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.04.009 · Cited by 142 · see citing works

An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis

Baggio, L. L., Huang, Q., Cao, X., & Drucker, D. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.017 · Cited by 137 · see citing works

The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice

Burmeister, M. A., Ayala, J. E., Smouse, H., Landivar-Rocha, A., Brown, J. D., Drucker, D. J., Stoffers, D. A., Sandoval, D. A., Seeley, R. J., & Ayala, J. E. (2017) · Diabetes · doi:10.2337/db16-1102 · Cited by 136 · see citing works

Vaccination against GIP for the Treatment of Obesity

Fulurija, A., Lutz, T. A., Sladko, K., Osto, M., Wielinga, P. Y., Bachmann, M. F., & Saudan, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003163 · Cited by 136 · see citing works

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms

Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133 · see citing works

Gastrointestinal hormones and regulation of gastric emptying

Camilleri, M. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000448 · Cited by 130 · see citing works

Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets

Gault, V. A., McClean, P. L., Cassidy, R. S., Irwin, N., & Flatt, P. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0710-4 · Cited by 127 · see citing works

Phenotypic flexibility as a measure of health: the optimal nutritional stress response test

Stroeve, J. H. M., van Wietmarschen, H., Kremer, B. H. A., van Ommen, B., & Wopereis, S. (2015) · Genes & Nutrition · doi:10.1007/s12263-015-0459-1 · Cited by 127 · see citing works

Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat–Fed Mice

Lamont, B. J., & Drucker, D. J. (2007) · Diabetes · doi:10.2337/db07-1202 · Cited by 127 · see citing works

Transforming obesity: The advancement of multi-receptor drugs

Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126 · see citing works

Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics

Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126 · see citing works

Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications

Irwin, N., & Flatt, P. R. (2009) · Diabetologia · doi:10.1007/s00125-009-1422-8 · Cited by 125 · see citing works

Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity

Miller, G. D. (2017) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617716376 · Cited by 126 · see citing works

Never waste a good crisis: confronting reproducibility in translational research

Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.006 · Cited by 117 · see citing works

Resistin Is a Key Mediator of Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Lipoprotein Lipase (LPL) Activity in Adipocytes

Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704896200 · Cited by 118 · see citing works

Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions

Watanabe, H., Enoki, Y., & Maruyama, T. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00513 · Cited by 118 · see citing works

GLP-1 based therapeutics: simultaneously combating T2DM and obesity

Heppner, K. M., & Pérez–Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 112 · see citing works

Incretin hormone mimetics and analogues in diabetes therapeutics

Green, B. D., & Flatt, P. R. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.003 · Cited by 113 · see citing works

The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action

Ayala, J. E., Bracy, D. P., James, F. D., Julien, B. M., Wasserman, D. H., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2008-0945 · Cited by 114 · see citing works

Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice

Himeno, T., Kamiya, H., Naruse, K., Harada, N., Ozaki, N., Seino, Y., Shibata, T., Kondo, M., Kato, J., Okawa, T., et al. (2011) · Diabetes · doi:10.2337/db10-1462 · Cited by 112 · see citing works

Prolonged saturated fat–induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver

Musso, G., Gambino, R., Pacini, G., De Michieli, F., & Cassader, M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26720 · Cited by 107 · see citing works

Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis

Ali, S., Lamont, B. J., Charron, M. J., & Drucker, D. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43615 · Cited by 109 · see citing works

G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus

Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108 · see citing works

Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition

Kaneko, K., Fu, Y., Lin, H.-Y., Cordonier, E. L., Mo, Q., Gao, Y., Yao, T., Naylor, J., Howard, V., Saito, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126107 · Cited by 106 · see citing works

The GLP-1 journey: from discovery science to therapeutic impact

Drucker, D. J. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175634 · Cited by 106 · see citing works

Therapeutic potential for GIP receptor agonists and antagonists

Irwin, N., & Flatt, P. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.001 · Cited by 105 · see citing works

Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action

Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104 · see citing works

The Glucagon-Like Peptide-1 Receptor Agonist Oxyntomodulin Enhances β-Cell Function but Does Not Inhibit Gastric Emptying in Mice

Maida, A., Lovshin, J. A., Baggio, L. L., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2008-0336 · Cited by 104 · see citing works

Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice

Irwin, N., McClean, P. L., O'Harte, F. P. M., Gault, V. A., Harriott, P., & Flatt, P. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0692-2 · Cited by 101 · see citing works

Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis

Mulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.007 · Cited by 102 · see citing works

Brain Glucagon-Like Peptide 1 Signaling Controls the Onset of High-Fat Diet-Induced Insulin Resistance and Reduces Energy Expenditure

Knauf, C., Cani, P. D., Ait-Belgnaoui, A., Bénani, A., Dray, C., Cabou, C., Colom, A., Uldry, M., Rastrelli, S., Sabatier, E., et al. (2008) · Endocrinology · doi:10.1210/en.2008-0180 · Cited by 99 · see citing works

GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: A randomised trial

Gögebakan, Ö., Osterhoff, M. A., Schüler, R., Pivovarova, O., Kruse, M., Seltmann, A.-C., Mosig, A. S., Rudovich, N., Nauck, M., & Pfeiffer, A. F. H. (2015) · Diabetologia · doi:10.1007/s00125-015-3618-4 · Cited by 95 · see citing works

Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance

Ayala, J. E., Bracy, D. P., James, F. D., Burmeister, M. A., Wasserman, D. H., & Drucker, D. J. (2010) · Endocrinology · doi:10.1210/en.2010-0289 · Cited by 95 · see citing works

Incretins in obesity and diabetes

Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93 · see citing works

Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet

Gault, V. A., Porter, W. D., Flatt, P. R., & Hölscher, C. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.59 · Cited by 93 · see citing works

Glucose-dependent insulinotropic polypeptide (GIP)

Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 99 · see citing works

K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease

Cho, Y. M., & Kieffer, T. J. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00004-7 · Cited by 93 · see citing works

Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists=antagonists?

Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94 · see citing works

Short-Term Effects of Liraglutide on Visceral Fat Adiposity, Appetite, and Food Preference: A Pilot Study of Obese Japanese Patients with Type 2 Diabetes

Inoue, K., Maeda, N., Kashine, S., Fujishima, Y., Kozawa, J., Hiuge-Shimizu, A., Okita, K., Imagawa, A., Funahashi, T., & Shimomura, I. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-109 · Cited by 89 · see citing works

Weight-loss diets modify glucose-dependent insulinotropic polypeptide receptor rs2287019 genotype effects on changes in body weight, fasting glucose, and insulin resistance: the Preventing Overweight Using Novel Dietary Strategies trial

Qi, Q., Bray, G. A., Hu, F. B., Sacks, F. M., & Qi, L. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.025270 · Cited by 87 · see citing works

Endoscopic sclerotherapy for the treatment of weight regain after Roux-en-Y gastric bypass: outcomes, complications, and predictors of response in 575 procedures

Dayyeh, B. K. A., Jirapinyo, P., Weitzner, Z. N., Barker, C. L., Flicker, M. S., Lautz, D. B., & Thompson, C. C. (2012) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2012.03.1407 · Cited by 85 · see citing works

Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism

Trzaskalski, N. A., Fadzeyeva, E., & Mulvihill, E. E. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420912972 · Cited by 86 · see citing works

Differential Importance of Glucose-Dependent Insulinotropic Polypeptide vs Glucagon-Like Peptide 1 Receptor Signaling for Beta Cell Survival in Mice

Maida, A., Hansotia, T., Longuet, C., Seino, Y., & Drucker, D. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.004 · Cited by 85 · see citing works

Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease

Musso, G., Gambino, R., & Cassader, M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.60.101107.134820 · Cited by 85 · see citing works

Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease

Yamaoka‐Tojo, M., Tojo, T., Takahira, N., Matsunaga, A., Aoyama, N., Masuda, T., & Izumi, T. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-17 · Cited by 84 · see citing works

GPR119 Regulates Murine Glucose Homeostasis Through Incretin Receptor-Dependent and Independent Mechanisms

Flock, G. B., Holland, D. P., Seino, Y., & Drucker, D. J. (2010) · Endocrinology · doi:10.1210/en.2010-1047 · Cited by 84 · see citing works

Satiety: a gut–brain–relationship

Barakat, G. M., Ramadan, W., Assi, G., & Khoury, N. B. E. (2024) · The Journal of Physiological Sciences · doi:10.1186/s12576-024-00904-9 · Cited by 82 · see citing works

Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.

Kyle, K., Willett, T., Baggio, L., Drucker, D., & Grynpas, M. (2011) · Endocrinology · doi:10.1210/en.2010-1098 · Cited by 78 · see citing works

Physiological roles of the GIP receptor in murine brown adipose tissue

Beaudry, J. L., Kaur, K. D., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Bates, H. E., Campbell, J. E., & Drucker, D. J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.006 · Cited by 70 · see citing works

GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue

Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F. M., et al. (2022) · Diabetes · doi:10.2337/db21-1166 · Cited by 70 · see citing works

Changes seen in gut bacteria content and distribution with obesity: causation or association?

Bell, D. S. H. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1098519 · Cited by 69 · see citing works

Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

Bifari, F., Manfrini, R., Dei, M., Berra, C., Siano, M., Zuin, M. G., Paroni, R. C., & Folli, F. B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 70 · see citing works

Dorothy Hodgkin Lecture 2008 Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity–diabetes?

Flatt, P. R. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02455.x · Cited by 68 · see citing works

Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture

Drucker, D. J. (2015) · Diabetes · doi:10.2337/db14-1514 · Cited by 68 · see citing works

Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective

Michałowska, J. M., Miller‐Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 69 · see citing works

Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice

Naitoh, R., Miyawaki, K., Harada, N., Mizunoya, W., Toyoda, K., Fushiki, T., Yamada, Y., Seino, Y., & Inagaki, N. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.052 · Cited by 68 · see citing works

Pharmacological antagonism of the incretin system protects against diet-induced obesity

Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67 · see citing works

Effects of peripheral administration of synthetic human glucose‐dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes

Daousi, C., Wilding, J. P. H., Aditya, S., Durham, B. H., Cleator, J., Pinkney, J. H., & Ranganath, L. R. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03451.x · Cited by 64 · see citing works

GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice

Hansotia, T., & Drucker, D. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.019 · Cited by 182 · see citing works

Insulin Action in the Double Incretin Receptor Knockout Mouse

Ayala, J. E., Bracy, D. P., Hansotia, T., Flock, G. B., Seino, Y., Wasserman, D. H., & Drucker, D. J. (2007) · Diabetes · doi:10.2337/db07-0704 · Cited by 36 · see citing works

Incretin hormone receptors are required for normal beta cell development and function in female mice

Omar, B. A., Ahlkvist, L., Yamada, Y., Seino, Y., & Åhrén, B. (2016) · Peptides · doi:10.1016/j.peptides.2016.03.012 · Cited by 9 · see citing works

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors

Åhrén, B., Yamada, Y., & Seino, Y. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz036 · Cited by 11 · see citing works

Contrasting roles for GLP-1R and GIPR in a model of diet-induced obesity

Gao, J., Cree, S., Ham, S., Nowell, C. J., Parker, A., Zhao, P., Whiting, L., Sloop, K. W., Samms, R. J., Sexton, P. M., et al. (2025) · Journal of Molecular Endocrinology · doi:10.1530/jme-25-0053